newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

  • Cogent Biosciences will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, at 11:05 a.m. ET.
  • A live webcast of the presentation will be available on the company's investor relations website with a replay archived for up to 30 days.
  • The Compensation Committee approved inducement equity grants to six new employees on May 26, 2026, under Nasdaq Listing Rule 5635(c)(4).
  • The aggregate grants include 25,500 nonqualified stock options with a 10-year term 4-year vesting schedule, plus 18,700 restricted stock units vesting annually over 4 years.
  • Cogent's lead clinical candidate bezuclastinib is a selective tyrosine kinase inhibitor targeting KIT D816V mutations associated with Systemic Mastocytosis.
  • The company is also developing therapies targeting exon 17 mutations in Gastrointestinal Stromal Tumors.
  • Cogent maintains a pipeline of novel targeted therapies aimed at ErbB2, PI3Kα, KRAS, and JAK2 mutations.
  • The company is headquartered in Waltham, Massachusetts, and Boulder, Colorado.